Silvia Damian

2.1k total citations
36 papers, 443 citations indexed

About

Silvia Damian is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Silvia Damian has authored 36 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 12 papers in Molecular Biology and 12 papers in Cancer Research. Recurrent topics in Silvia Damian's work include Cancer Treatment and Pharmacology (7 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Silvia Damian is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Silvia Damian collaborates with scholars based in Italy, United States and France. Silvia Damian's co-authors include Sara Cresta, Filippo de Braud, Élena Elez, Jonathan D. Cheng, John M. Wallmark, Ruey‐Long Hong, Pradeep Thanigaimani, Sarina A. Piha‐Paul, Bhumsuk Keam and Stephen V. Liu and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Silvia Damian

31 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Silvia Damian Italy	10	272	149	143	124	56	36	443
Gustavo Schvartsman Brazil	11	370 1.4×	118 0.8×	101 0.7×	201 1.6×	42 0.8×	31	488
Bernardo Goulart United States	8	294 1.1×	109 0.7×	98 0.7×	75 0.6×	43 0.8×	10	566
Takanori Kanematsu Japan	14	297 1.1×	104 0.7×	149 1.0×	253 2.0×	69 1.2×	28	559
Yanfen Feng China	14	201 0.7×	72 0.5×	130 0.9×	88 0.7×	85 1.5×	39	429
Hidekazu Hirano Japan	12	368 1.4×	158 1.1×	141 1.0×	225 1.8×	74 1.3×	91	586
Eduardo Caetano Albino da Silva Brazil	11	123 0.5×	104 0.7×	140 1.0×	122 1.0×	102 1.8×	28	350
Hongjiang Yan China	14	257 0.9×	232 1.6×	159 1.1×	110 0.9×	118 2.1×	33	543
Bhumsuk Keam South Korea	9	312 1.1×	48 0.3×	98 0.7×	134 1.1×	56 1.0×	17	568
Lucia Raimondo Italy	8	185 0.7×	66 0.4×	204 1.4×	105 0.8×	55 1.0×	15	387
Mina Waraya Japan	15	196 0.7×	124 0.8×	279 2.0×	79 0.6×	122 2.2×	30	514

Countries citing papers authored by Silvia Damian

Since Specialization

Citations

This map shows the geographic impact of Silvia Damian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Damian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Damian more than expected).

Fields of papers citing papers by Silvia Damian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Damian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Damian. The network helps show where Silvia Damian may publish in the future.

Co-authorship network of co-authors of Silvia Damian

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Damian. A scholar is included among the top collaborators of Silvia Damian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Damian. Silvia Damian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Damian, Silvia, Domenica Lorusso, Krisztián Homicskó, et al.. (2025). Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC).. Journal of Clinical Oncology. 43(16_suppl). 5514–5514.

Lorusso, Domenica, Silvia Damian, Ilaria Colombo, et al.. (2025). Interim safety and antitumor activity data from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with metastatic recurrent endometrial cancer.. Journal of Clinical Oncology. 43(16_suppl). 5603–5603.

Lorenzini, Daniele, Chiara Costanza Volpi, Monica Niger, et al.. (2025). Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization. Tumori Journal. 111(4). 322–330. 1 indexed citations

Luke, Jason J., Karen A. Gelmon, Lillian L. Siu, et al.. (2024). Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. Clinical Cancer Research. 31(11). 2134–2144. 8 indexed citations

Damian, Silvia, et al.. (2024). Nurses' Experiences in Caring Diabetic Ketoacidosis Patients in the Emergency Departments: A Qualitative Study. 10(1).

Rivoltini, Licia, Chiara Camisaschi, Giovanni Fucà, et al.. (2024). Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade. Scientific Reports. 14(1). 3379–3379. 6 indexed citations

Rodón, Jordi, Silvia Damian, Muhammad Furqan, et al.. (2024). Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature Medicine. 30(6). 1645–1654. 24 indexed citations

Capone, Iolanda, Fabio Bozzi, Gian Paolo Dagrada, et al.. (2022). Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples. SHILAP Revista de lepidopterología. 3(5). 582–597. 3 indexed citations

Damian, Silvia, et al.. (2022). NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma. European Journal of Cancer. 174. S2–S2. 1 indexed citations

10.

Greil, Richard, Maja J.A. de Jonge, David S.P. Tan, et al.. (2021). 436P Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC). Annals of Oncology. 32. S552–S553. 2 indexed citations

11.

Ambrosini, Margherita, Giovanni Fucà, Matteo Duca, et al.. (2021). Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?. Critical Reviews in Oncology/Hematology. 169. 103532–103532. 4 indexed citations

12.

Malacrida, Alessio, R Rigolio, Luigi Celio, et al.. (2021). In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells. International Journal of Molecular Sciences. 22(15). 8230–8230. 5 indexed citations

13.

Mariani, Gabriella, Giulia Galli, Stefano Cavalieri, et al.. (2019). Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study. The Breast Journal. 25(2). 237–242. 3 indexed citations

14.

Schöffski, Patrick, Sara Cresta, Ingrid A. Mayer, et al.. (2018). A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Research. 20(1). 109–109. 67 indexed citations

15.

Tessari, Anna, Lorenzo Pilla, Silvia Damian, et al.. (2018). Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?. The Breast. 42. 68–73. 27 indexed citations

16.

Mariani, Gabriella, Giulia Galli, Stefano Cavalieri, et al.. (2017). Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC). Annals of Oncology. 28. vi34–vi34. 1 indexed citations

17.

Azaro, Analía, Jordi Rodón, Jean‐Pascal Machiels, et al.. (2016). A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. Cancer Chemotherapy and Pharmacology. 78(6). 1185–1197. 2 indexed citations

18.

Cona, Maria Silvia, Alice Indini, Sara Cresta, et al.. (2015). Druggable aberrations in solid tumors: an overview on ALK and ROS-1 status. Annals of Oncology. 26. vi143–vi143. 1 indexed citations

19.

Agustoni, Francesco, et al.. (2014). Folfirinox in Pancreatic Cancer: the National Cancer Institute of Milan Single Experience. Annals of Oncology. 25. ii50–ii50. 1 indexed citations

20.

Ong, Michael, Gianluca Del Conte, Rastislav Bahleda, et al.. (2013). A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2535–2535. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact